
Kala Pharmaceuticals KALA
$ 0.2
-6.67%
Quarterly report 2025-Q3
added 11-19-2025
Kala Pharmaceuticals Gross Profit 2011-2026 | KALA
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit Kala Pharmaceuticals
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 3.19 M | 4.07 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 4.07 M | 3.19 M | 3.63 M |
Gross Profit of other stocks in the Biotechnology industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
180 M | - | 2.43 % | $ 254 M | ||
|
Aeterna Zentaris
AEZS
|
4.73 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
102 K | - | -10.17 % | $ 12.2 K | ||
|
AIkido Pharma
AIKI
|
10 K | - | 1.93 % | $ 17.4 M | ||
|
Amarin Corporation plc
AMRN
|
121 M | $ 14.67 | -0.07 % | $ 6.09 B | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
5.52 B | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
5.51 M | - | 2.54 % | $ 160 B | ||
|
Albireo Pharma
ALBO
|
39.2 M | - | -0.23 % | $ 916 M | ||
|
Aptinyx
APTX
|
1.56 K | - | -39.0 % | $ 4.57 M | ||
|
Midatech Pharma plc
MTP
|
-428 K | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
12.1 | - | -1.52 % | $ 24.7 M | ||
|
Arena Pharmaceuticals
ARNA
|
319 K | - | -6.81 % | $ 3.04 B | ||
|
Ayala Pharmaceuticals
AYLA
|
90 K | - | - | $ 7.46 M | ||
|
Acorda Therapeutics
ACOR
|
119 M | - | -24.86 % | $ 820 K | ||
|
bluebird bio
BLUE
|
-4.03 M | - | - | $ 546 M | ||
|
Acasti Pharma
ACST
|
-32.3 K | - | 4.01 % | $ 150 M | ||
|
Институт стволовых клеток человека
ISKJ
|
774 M | - | - | - | ||
|
Cabaletta Bio
CABA
|
0.006 | $ 2.82 | 1.44 % | $ 283 M | ||
|
Avid Bioservices
CDMO
|
7.32 M | - | - | $ 789 M | ||
|
Adverum Biotechnologies
ADVM
|
2.32 M | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
1.27 M | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
90 K | - | -9.65 % | $ 45.9 M | ||
|
CEL-SCI Corporation
CVM
|
255 K | $ 3.47 | -1.7 % | $ 221 M | ||
|
BeiGene, Ltd.
BGNE
|
4.67 B | - | 0.49 % | $ 251 B | ||
|
BioDelivery Sciences International
BDSI
|
14 M | - | -4.8 % | $ 255 M | ||
|
ChemoCentryx
CCXI
|
64.9 M | - | - | $ 3.74 B | ||
|
Enochian Biosciences
ENOB
|
37.5 K | - | - | $ 40.5 M | ||
|
CureVac N.V.
CVAC
|
-10.6 M | - | - | $ 867 M | ||
|
Esperion Therapeutics
ESPR
|
225 M | $ 2.85 | 3.26 % | $ 592 M | ||
|
Eton Pharmaceuticals
ETON
|
42.7 M | $ 23.45 | -1.64 % | $ 631 M | ||
|
China SXT Pharmaceuticals
SXTC
|
367 K | $ 1.32 | -5.2 % | $ 1.88 M | ||
|
Arbutus Biopharma Corporation
ABUS
|
-40.6 M | $ 4.45 | -1.77 % | $ 853 M |